This article is more than 5 years old. Information may no longer be current.
MedImmune joins Human Vaccines Project
Click Here to Manage Email Alerts
MedImmune, the biologics research and development arm of AstraZeneca, recently joined the Human Vaccines Project to develop vaccines and immunotherapies for infectious diseases and cancer, according to a press release.
The Human Vaccines Project aims to accelerate vaccine development by deciphering the human immune system with the support of leading academic research centers, governments and nonprofit groups.
“Engagement with leading industry partners such as MedImmune is central to achieving the project’s ultimate goal of revolutionizing vaccine and immunotherapy development to create a new paradigm for global disease prevention,” Wayne C. Koff, PhD, chief scientific officer for the International AIDS Vaccine Initiative (IAVI) and co-founder of the Human Vaccines Project, said in the release.
Numerous small clinical trials investigating the immune system will be conducted through the project’s Rule of Immunogenicity program. Researchers will develop highly targeted therapies by sequencing components of the immune system in diverse populations during the project’s 7- to 10-year Human Immunome program.
The Human Vaccines Project is headquartered at the International AIDS Vaccine Initiative, and is endorsed by 35 leading vaccine researchers, according to the release. The association also is supported by the Robert Wood Johnson Foundation, GlaxoSmithKline, Aeras, and Vanderbilt University Medical Center.